Page 51 - IMO-2-1

Innovative Medicines & Omics Current approach in the management of kidney disease

capitata is less studied, although extracts from its leaves and with a specific administration route could enhance their
stems, as well as the roots of Asparagus racemosus (family effectiveness, as they may provide additive nephroprotective
Asparagaceae), are used for urinary tract and KD due to effects. Future research focused on molecular pathway will
the presence of bioactive compounds, including quercetin, be necessary to determine the effect of these treatments.
apigenin, resveratrol, quercetin-3-D-galactoside,
3,3’,4’-trihydroxyflavone (synonym 5,7-dideoxyquercetin), Acknowledgments
and 6-methyldihydroquercetin. 74-76 The authors acknowledge to Dr. Pradip Ghosh, Director,

3.8. Glucagon-like peptide 1 receptor agonists Midnapore City College for essential support, a well-
(GLP-1RAs) organized work environment, and laboratory facilities for
conducting related research work. The authors are also
The human GLP-1RAs are stimulated by the pharmaceutical grateful to Indian Council for Medical Research (ICMR)
class of peptides known as GLP-1RAs. There is debate for providing fund.
regarding whether GLP-1RAs affect glomerular
hemodynamics. GLP-1RAs may reduce glomerular Funding
hyperfiltration by reducing vasoconstriction induced by None.
endothelin-1 and Angiotensin II. However, in theory,
tubule-glomerular feedback would cause vasoconstriction Conflict of interest
of the pre-glomerular arteriole in response to reduced
proximal salt reabsorption. However, the current study The authors declare that they have no competing interests.
found that exenatide had a net vasodilatory impact on
pre-glomerular arterioles, indicating a greater direct Author contributions
vasodilation effect. According to these results, GLP- Conceptualization: Suchismita Roy
1RAs are renal vasodilators and proximal diuretics that, Visualization: Sahadeb Jana, Kaberi Kandar
in healthy individuals, have a negligible effect on tubule- Writing – original draft: Suchismita Roy, Palash Mitra
glomerular feedback. It is probable that GLP-1 protects Writing – review & editing: Suchismita Roy, Malay Kumar
the renal system from damage caused by oxidation Patsa
because GLP-1R activation stimulates the cyclic adenosine
monophosphate–protein kinase A pathway, which results Ethics approval and consent to participate
in antioxidative actions. GLP-1RAs also decreased the Not applicable.
40
expression of a number of inflammatory markers in rats
in a diabetic nephropathy model, including collagen I, Consent for publication
alpha-smooth muscle actin, tubulointerstitial TNF-alpha,
MCP-1, fibronectin, and prevented tubulointerstitial Not applicable.
lesions. These biomarkers have all been linked to diabetic Availability of data
nephropathy. 77
Not applicable.
4. Conclusion
References
Research on the prevention and protection of slow-
progressing renal illnesses has been carried out globally. 1. Bellomo R, Kellum JA, Ronco C. Acute kidney injury.
At present, dialysis and kidney transplantation are the Lancet. 2012;380(9843):756-766.
primary treatments for KD, but these options are very doi: 10.1016/S0140-6736(11)61454-2
expensive and have a number of drawbacks. In light of 2. Canaud G, Bonventre JV. Cell cycle arrest and the evolution
these challenges, further research is required to prevent of chronic kidney disease from acute kidney injury. Nephrol
and treat ESKD and to prolong the lives of KD patients. Dial Transplant. 2015;30(4):575-583.
The current research on KD shows potential for opening
new pathway to reduce the global burden of KD. doi: 10.1093/ndt/gfu230
3. Guzzi F, Cirillo L, Roperto RM, Romagnani P, Lazzeri E.
This review primarily highlights that ACEIs, ARBs, Molecular mechanisms of the acute kidney injury to chronic
renin inhibitors, apoptosis-based treatment strategies, kidney disease transition: An updated view. Int J Mol Sci.
phytomedicines, JAK/STAT inhibition, and TNF inhibition 2019;20(19):4941.
may offer nephroprotective effects well beyond their main
indications for diabetic nephropathy, kidney cancer, doi: 10.3390/ijms20194941
AKI, and CKD. Moreover, combining these therapies 4. Ohlmeier C, Schuchhardt J, Bauer C, et al. Risk of chronic

Volume 2 Issue 1 (2025) 45 doi: 10.36922/imo.4969